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ARTICLE

Sarm1 activation produces cADPR to increase
intra-axonal Ca++ and promote axon degeneration in
PIPN

Cancer patients frequently develop chemotherapy-induced peripheral neuropathy (CIPN), a painful and long-lasting disorder
with profound somatosensory deficits. There are no effective therapies to prevent or treat this disorder. Pathologically, CIPN is
characterized by a “dying-back” axonopathy that begins at intra-epidermal nerve terminals of sensory neurons and
progresses in a retrograde fashion. Calcium dysregulation constitutes a critical event in CIPN, but it is not known how
chemotherapies such as paclitaxel alter intra-axonal calcium and cause degeneration. Here, we demonstrate that paclitaxel
triggers Sarm1-dependent cADPR production in distal axons, promoting intra-axonal calcium flux from both intracellular and
extracellular calcium stores. Genetic or pharmacologic antagonists of cADPR signaling prevent paclitaxel-induced axon
degeneration and allodynia symptoms, without mitigating the anti-neoplastic efficacy of paclitaxel. Our data demonstrate that
cADPR is a calcium-modulating factor that promotes paclitaxel-induced axon degeneration and suggest that targeting cADPR
signaling provides a potential therapeutic approach for treating paclitaxel-induced peripheral neuropathy (PIPN).

Introduction
Axons provide critical long-distance connections among neurons. Functional and structural defects in these connections,
known as axonopathy, are a hallmark of many central and peripheral neurodegenerative diseases. Toxins, disease, or injury
can all initiate local signaling cascades, leading to dysfunction
and destruction of the affected axons. Axon degeneration often
begins at axon terminals and progresses in a retrograde direction
toward the neuron cell bodies, a process known as “dying-back”
degeneration (Wang et al., 2012). Dying-back axon degeneration is
a key pathological feature observed in cancer patients suffering
from chemotherapy-induced peripheral neuropathy (CIPN;
Fukuda et al., 2017). The most common manifestations of
CIPN are excess pain and deficits of sensation in a stocking
and glove distribution, in which the distal limbs are most
significantly affected (Schneider et al., 2015; Seretny et al.,
2014). Although CIPN is often reversible over time, a significant
fraction of patients develop long-lasting, untreatable pain and

severe sensory deficits persisting for years after the cessation of
cancer treatment (Dorsey et al., 2019). Defective axonal transport,
mitochondrial dysfunction, and intra-axonal calcium dysregulation have all been implicated as key events in the process of
chemotherapy-induced axon degeneration (Berbusse et al., 2016;
Bobylev et al., 2015; Boehmerle et al., 2007; Pease-Raissi et al.,
2017). However, it remains unclear how these processes coordinate with one another to cause degeneration. Given the lack of
understanding of the underlying mechanisms, it is not surprising
that there are no effective treatments available for CIPN. Methods
of mitigating CIPN are currently limited to dose reduction or early
termination of chemotherapy, which compromises the therapeutic response and patient survival (Dorsey et al., 2019). Thus, there
is an urgent need for improved understanding of CIPN mechanisms and discovery of effective therapeutic targets.
Recent insights into the mechanism of axon degeneration caused
by physical injury provide important clues for understanding axon
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neuroblastoma cells and dorsal root ganglion (DRG) primary
cultures (Benbow et al., 2012; Boehmerle et al., 2007; PeaseRaissi et al., 2017), while depletion of calcium channels or inhibition of calpain, a calcium-dependent protease, prevents
paclitaxel-induced axon degeneration (Pease-Raissi et al., 2017;
Wang et al., 2004). These data collectively identify calcium
dysregulation as a key component of axon degeneration induced by both chemotherapy and injury. However, current
studies lack direct observation of calcium changes within axons
following chemotherapy drug treatment and have not identified the sources of calcium that contribute to degeneration.
Here, we directly visualized intra-axonal calcium changes
following paclitaxel treatment using GCaMP6s targeted to axons
of sensory neurons in microfluidic chambers. We found that
paclitaxel leads to Sarm1 activation and excess cADPR production, which contributes to paclitaxel-induced intra-axonal calcium flux and degeneration. We found that interference with
cADPR signaling using genetic or pharmacologic intervention
prevents paclitaxel or Sarm1 activation-triggered axonal calcium
elevation and degeneration in cultured sensory neurons. Finally,
we showed that a cADPR antagonist attenuates paclitaxelinduced neuropathy in vivo without affecting the anti-tumor
efficacy of paclitaxel. Our data provide new insights into the
molecular mechanisms of paclitaxel-induced peripheral neuropathy and suggest cADPR as a promising therapeutic target
for treating paclitaxel-induced peripheral neuropathy.

Results
Paclitaxel treatment increases cADPR levels through
Sarm1 activation
Local paclitaxel treatment of the axons of sensory neurons in
compartmentalized cultures leads to axon degeneration in DRG
neurons (Fig. 1 A; Gornstein and Schwarz, 2017; Pease-Raissi
et al., 2017; Yang et al., 2009). This axon degeneration was
quantified as the ratio of fragmented axons normalized to total
axon area (Fig. 1 B). In contrast, paclitaxel-induced axon degeneration was prevented in Sarm1 shRNA-transduced DRG
neurons (Fig. 1, A and B; and Fig. S1 D). The efficiency of Sarm1
shRNA was verified at both the mRNA and protein levels (Fig. S1,
A and B). This result demonstrates that Sarm1 is required for
paclitaxel-induced axon degeneration in a cell autonomous
fashion; moreover, the compartmentalized culture system
provides a good in vitro model to address the mechanisms of
Sarm1-dependent axon degeneration.
As activated, Sarm1 catalyzes the breakdown of NAD and
NADP to generate cADPR and ADPR, we asked whether paclitaxel affects NAD and its metabolites. Paclitaxel treatment of
DRG sensory neuron cultures significantly decreased NAD and
NADP levels as measured via liquid chromatography–tandem
mass spectrometry (LC-MS/MS; Fig. 1, D and E). Knockdown of
Sarm1 increased baseline NAD levels in vehicle-treated and
paclitaxel-treated cultures and restored NAD and NADP levels in
paclitaxel-treated cultures to the same level as seen in the untreated control group (Fig. 1, D and E; Table S1; and Table S2).
Interestingly, comparing cultures with Sarm1 knockdown that
were treated with vehicle and those treated with paclitaxel
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degeneration due to chemotherapy. Studies of Wallerian degeneration in Drosophila, zebrafish, and mammalian models
have identified Sterile α and Toll/Interleukin-1 Receptor (TIR)
motif–containing 1 (Sarm1) as a key mediator of injury-induced
axonal degeneration (Gerdts et al., 2015, 2013; Osterloh et al.,
2012; Tian et al., 2020). Loss of Sarm1 also protects against
diabetes, glaucoma, and chemotherapy-induced neuropathy
(Cetinkaya-Fisgin et al., 2020; Geisler et al., 2019a, 2016; Ko
et al., 2020; Turkiew et al., 2017), suggesting a convergent
pathway among axon degeneration induced by injury, chemotherapy, and metabolic disorder. Sarm1 functions as a nicotinamide adenine dinucleotide (NAD) hydrolase, hydrolyzing
NAD to generate nicotinamide (NAM), cyclic-ADP Ribose
(cADPR), and ADP Ribose (ADPR; Essuman et al., 2017). The
catalytic domain of Sarm1 is located in the C-terminal TIR domain (Essuman et al., 2017). Activation of the TIR domain by
dimerization is sufficient to trigger axon degeneration (Gerdts
et al., 2015). Conversely, mutations that enzymatically disable
Sarm1 prevent axotomy-induced axon degeneration (Essuman
et al., 2017; Geisler et al., 2019b; Summers et al., 2016). These
findings indicate the NADase activity of Sarm1 is both necessary and sufficient for its pro-degenerative function. The
question remains whether Sarm1-dependent axon degeneration is exclusively due to NAD loss and subsequent metabolic
catastrophe or whether NAD-derived metabolites such as
cADPR and ADPR also contribute to degeneration. Studies of
Wallerian degeneration demonstrated that cADPR is a biomarker for Sarm1 activity but does not by itself trigger axon
degeneration (Sasaki et al., 2020). A recent study showed that
NAD breakdown products signal cell death following TIR domains’ activation in plants (Wan et al., 2019), suggesting excess
cADPR and ADPR production can contribute to the degenerative process. However, it is not clear whether cADPR may
contribute to slowly progressing types of Sarm1-dependent
degeneration such as those caused by chemotherapies. cADPR
is a calcium-mobilizing agent that potentiates calcium-induced
calcium release in sea urchin egg homogenate (Clapper et al.,
1987; Lee, 1993, 1989) and in other cell types, including T lymphocytes (Guse et al., 1999), cardiac myocytes (Rakovic et al.,
1996), and neurons (Currie et al., 1992; Higashida et al., 2001).
Studies using pharmacological approaches or in vitro reconstitution of channels have shown that cADPR modulates intracellular calcium release through ryanodine receptor channels
(RyRs) but not inositol 1,4,5-trisphosphate receptors (IP3Rs;
Clapper et al., 1987; Dargie et al., 1990; Mészáros et al., 1993).
Moreover, both cADPR and ADPR activate TRPM2, a calciumpermeable, nonspecific cation channel located predominantly
on the plasma membrane (Kolisek et al., 2005; Yu et al., 2019).
These observations raise the possibility that cADPR and ADPR,
the products of activated Sarm1, may not merely be readouts of
Sarm1 but may constitute signaling molecules that contribute to
axonal calcium dysregulation and degeneration.
Axotomy rapidly induces increased axonal calcium flux
(Adalbert et al., 2012; Loreto et al., 2015; Vargas et al., 2015), and
both extracellular and intracellular calcium stores are involved
(Villegas et al., 2014). Paclitaxel and vincristine, two microtubuletargeting chemo-drugs, alter ATP-induced calcium release in
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Figure 1. Paclitaxel-induced cADPR production and axon degeneration require Sarm1 but not CD38. (A) Tuj1 immunostaining and corresponding binarized images of axon endings of DRG neurons grown in compartmented cultures. Following lentiviral infection with shRNA against Sarm1 or CD38 or control
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shRNA (Ctl), 30 nM paclitaxel (Pac) or vehicle control (Veh) was applied to axons for 24 h. White boxes outline regions shown at higher magnification in the
center panels. White stars indicate fragmented region of axons displayed as interruptions in Tuj1 continuity. Scale bar: 20 µm (left and right panels), 50 µm
(middle insets). See Fig. S1 C for representative images of vehicle-treated axons expressing Sarm1 or CD38 shRNA. (B and C) Quantification of the degeneration
index of A in DRG neurons with Sarm1 knockdown (B) and CD38 knockdown (C): ratio of area of fragmented axons to total axon area (degeneration index). Data
represent mean ± SEM; individual data points are shown. N represents number of images. Data are pooled from three (B) and five (C) independent experiments.
**, P < 0.01; ***, P < 0.001 by two-way ANOVA with Tukey’s multiple comparisons test. (D–F) Level of NAD (D), NADP (E), and cADPR (F) in DRG neurons
cultured for 24 h with 600 nM paclitaxel (Pac) or DMSO (Veh) following lentiviral infection with shRNA to Sarm1 or CD38 or control shRNA. Data represent
mean ± SEM; individual data points are shown. N represents number of independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 by
two-way ANOVA with Tukey’s multiple comparison test. (G–I) Levels of NAD (G), NADP (H), and cADPR (I) in distal axons (DA) and cell bodies (CB) of DRG
neurons after 24 h of 30 nM paclitaxel (Pac) or DMSO (Veh) applied to axons. Data represent mean ± SEM; individual data points are shown. N represents
number of independent experiments. *, P < 0.05; **, P < 0.01; ****, P < 0.0001; two-way ANOVA, Tukey’s multiple comparisons test.
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significantly increased cADPR levels in distal axons but not in
cell bodies (Fig. 1 I), while NAD and NADP levels showed small
decreases in both distal axons and cell bodies (Fig. 1, G and H).
We also found that ADPR, the other breakdown component of
NAD, was not affected by paclitaxel in either cell bodies or distal
axons (Fig. S1 E). These results demonstrate that the local accumulation of cADPR in axons correlates with paclitaxelinduced axon degeneration.
Paclitaxel leads to Sarm1-dependent axonal calcium flux
Calcium dysregulation is a critical step in the process of axon
degeneration. However, there is no direct evidence showing
paclitaxel changes axonal calcium flux. As cADPR can potentiate
calcium release from intracellular stores (Clapper et al., 1987;
Lee et al., 1989), the paclitaxel-induced increase in cADPR in
distal axons could alter intra-axonal calcium flux. To monitor
axonal calcium alterations in space and time, we cultured DRG
neurons in microfluidics and transduced the neurons with
AAV9-expressing axon-localizing GCaMP6s containing a sequence from GAP-43 that targets the protein to axons, followed
by a P2A peptide–linked mRuby3 (AAV9-GCaMP6s-mRuby3;
Broussard et al., 2018). This allows us to normalize the calcium
GCaMP6s fluorescence to the level of mRuby3 expression within
axons at each time point. Simultaneously, we transduced the
DRG cells with lentivirus expressing Sarm1 shRNA or Turbogreen fluorescent protein (tGFP)–targeted control shRNA. A
recent study indicates that changes in substrate may alter the
timing and dose responses of paclitaxel-induced axon degeneration (Shin et al., 2021). As the substrate in microfluidic cultures
consists of laminin, rather than the Matrigel used in Campenot
cultures, we used the higher dose of paclitaxel that is required
for degeneration in noncompartmental cultures (600 nM) and
causes axon retraction in microfluidic chambers (Fig. S2, A and
B). We imaged GCaMP6s and mRuby3 signals at multiple time
points in the same location over the course of 48 h of paclitaxel
or vehicle treatment. At each time point, the GCaMP6s signal
was normalized to mRuby3 signal (GCaMP6s/mRuby3), and this
ratio was then normalized to GCaMP6s/mRuby3 at time 0
[(GCaMP6s/mRuby3)0]. We found that paclitaxel gradually
increases axonal calcium signal (Fig. 2, A and B), and this is
followed by axon degeneration (Fig. S2 C, white arrowheads).
In sensory neurons, knockdown of Sarm1 prevented paclitaxelinduced axonal calcium elevation (Fig. 2, A and B; and Fig. S2 C),
indicating that Sarm1 is required for paclitaxel-induced axonal
calcium flux. As CD38 depletion enhances the increase in cADPR
Journal of Cell Biology
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showed that paclitaxel still significantly decreased NAD and
NADP in these Sarm1-depleted DRG neurons (Fig. 1, D and E;
Table S1; and Table S2). Paclitaxel treatment also significantly
increased cADPR levels (Fig. 1 F and Table S3), the product of NAD
hydrolysis and a validated biomarker of SARM1 activity (Sasaki
et al., 2020). Sarm1 depletion inhibited paclitaxel-induced cADPR
production and restored cADPR to the same level as seen in the
untreated control group (Fig. 1 F and Table S3). In contrast to NAD
and NADP levels, paclitaxel does not cause any significant increase
of cADPR in Sarm1-depleted DRG neurons.
We asked how these metabolic changes contribute to
paclitaxel-induced axon degeneration. One possibility is that
excess NAD and NADP consumption leads to insufficient energy
supply and axon maintenance failure, thereby triggering degeneration. To investigate whether the absolute levels of NAD and
NADP are critical for paclitaxel-induced axon degeneration, we
tested the neuroprotective effect of CD38, another NADase (Aksoy
et al., 2006). Similar to Sarm1, knockdown of CD38 increases the
NAD levels in both vehicle- and paclitaxel-treated cultures, which
restored NAD and NADP in paclitaxel-treated cultures to the levels
seen in the vehicle-treated control cultures (Fig. 1, D and E; and
Fig. S1 C). As seen for Sarm1 knockdown, comparing cultures with
CD38 knockdown that were treated with vehicle and those treated
with paclitaxel showed that paclitaxel still significantly decreases
NAD and NADP in these CD38-depleted DRG neurons. However,
unlike Sarm1 depletion, CD38 depletion failed to block paclitaxelinduced degeneration (Fig. 1, A and C; and Fig. S1 D). This result is
consistent with the previous finding that murine CD38−/− neurons
were not protected from axotomy (Sasaki et al., 2009). These data
collectively suggest that neither the absolute levels nor the relative
reduction of NAD and NADP is a critical determinant of paclitaxelinduced axon degeneration.
Surprisingly, rather than inhibiting cADPR production,
CD38-deficient DRG neurons showed enhanced cADPR elevation
when treated with paclitaxel (Fig. 1 F). This was a synergistic
effect with paclitaxel, as CD38 depletion alone did not alter basal
levels of cADPR (Fig. 1 F). Since CD38 functions as both an NADase
and a cADPR hydrolase (Chini, 2009), it is possible that excess
cADPR produced by paclitaxel-induced Sarm1 activity accumulates further upon CD38 deficiency. The differential effects of
Sarm1 and CD38 on cADPR production raise the possibility that
cADPR itself contributes to paclitaxel-induced degeneration.
We then evaluated the subcellular localization of paclitaxelinduced metabolites using sensory neurons in the compartmentalized culture systems. Axonal treatment with paclitaxel

4 of 19

Downloaded from http://rupress.org/jcb/article-pdf/221/2/e202106080/1427212/jcb_202106080.pdf by Washington University In St. Louis Libraries user on 09 March 2022

Figure 2. Paclitaxel leads to Sarm1-dependent increase in axonal calcium. (A and C) Representative images of GCaMP6s (green) and mRuby3 (red) in
axons of DRG neurons also expressing indicated shRNA at 36 h (A) and 48 h (C) after 600 nM paclitaxel (Pac) or vehicle control (Veh) was applied to axons.
White arrowhead indicates axon with elevated calcium signal. This axon later degenerates (also see Fig. S2 A). Scale bar: 20 µM. (B and D) Quantification of
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calcium signal calculated as (GCaMP6s/mRuby3)/(GCaMP6s/mRuby3)0. (GCaMP6s/mRuby3) represents calcium signal at each time point, and (GCaMP6s/
mRuby3)0 represents calcium signal at time 0 before treatment. Data represent mean ± SEM. N represents number of images. 8–10 images from each sample
per experiment; one or two samples per condition per experiment. Data pooled from four independent experiments. Three experiments from D share the same
control shRNA samples with B. *, P < 0.05; **, P < 0.01; ***, P < 0.001; by two-way ANOVA with Tukey’s multiple comparisons test for each time point.
(E) Representative images of GCaMP6s (green) and mRuby3 (red) of DRG axons treated with DMSO, 600 nM paclitaxel alone, or 600 nM paclitaxel with 20 µM
8-Br–cADPR. Scale bar: 20 µm. (F) Quantification of calcium signal of DRG axons treated with DMSO, 600 nM paclitaxel, 600 nM paclitaxel with 20 µM
8-Br–cADPR, or 20 µM 8-Br–cADPR. Data represent mean ± SEM. N represents number of images. 8–10 images for each sample per experiment. Data pooled
from 14 independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 by two-way ANOVA with Tukey’s multiple comparisons test for
each time point. Ctl, control.

Sarm1 activation triggers axonal calcium flux
We then asked whether Sarm1 activation is not only necessary
but is also sufficient to increase axonal calcium flux. We transduced DRG neurons with AAV9-GCaMP6s-mRuby3 together
with lentivirus expressing the Sarm1 TIR domain (sTIR) linked
to FkbpF36V, so homodimerization and enzymatic activation of
the Sarm1 NADase can be triggered upon addition of B/B homodimerizer (FkbpF36V; Gerdts et al., 2015; see Fig. S3 A for
illustration). Dimerization of this TIR domain activates the enzyme, generating cADPR (Fig. 3 A), and causes axon degeneration within 2–6 h (Gerdts et al., 2015). Axonal calcium signals
started to increase ∼2 h after B/B homodimerizer was added to
the axon chamber, and signal continued to increase throughout
the 4-h time window (Fig. 3, B and C). As a control, dimerization
of FkbpF36V-tagged MYD88 TIR domain (mTIR), which does not
possess NADase activity or induce axon degeneration (Gerdts
et al., 2015), failed to trigger intra-axonal calcium elevation
(Fig. 3, B and C). These data together indicate that Sarm1 is
necessary and sufficient for axonal calcium elevation. We found
that axonal treatment with 8-Br–cADPR partially inhibited axonal calcium elevation caused by sTIR dimerization (Fig. 3, B and
C). We tested a second cADPR antagonist, 8-Br-7-CH–cADPR,
which similarly showed partial inhibition of calcium elevation
caused by sTIR dimerization (Fig. 3 D). The partial rescue by
Li et al.
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cADPR antagonists indicates that cADPR contributes to calcium
modulation in axons, but it is not the only factor that is involved
in the calcium flux initiated by paclitaxel treatment or by Sarm1
activation. cADPR is known to modulate calcium release in a
calcium-induced calcium release manner (Galione et al., 1991),
and our data are consistent with a model in which cADPR
functions as a calcium modulator that enhances calcium release
and synergizes with other factors (Galione and White, 1994) to
induce axon degeneration.
cADPR antagonists are neuroprotective in vitro
To investigate this model and determine whether cADPRdependent calcium mobilization contributes to axon degeneration downstream of paclitaxel, we tested the neuroprotective
effect of 8-Br–cADPR in compartmentalized cultures. Axonal
treatment with 8-Br–cADPR significantly decreased paclitaxelinduced degeneration in a concentration-dependent manner
(Fig. 4, A and B). We also tested the more potent cADPR antagonist 8-Br-7-CH–cADPR (Moreau et al., 2011). Axonal treatment
with 8-Br-7-CH–cADPR significantly decreased paclitaxel-induced
degeneration at concentrations as low as 0.1 µM (Fig. 4 C), further
implicating cADPR in paclitaxel-induced axon degeneration. One
alternative explanation of our results is that 8-Br–cADPR could
function as a direct inhibitor of Sarm1 and thereby suppress
cADPR production. An in vitro Sarm1 activity assay using purified
Sarm1 protein supplemented with NAD and nicotinamide mononucleotide (NMN) demonstrated that 8-Br–cADPR did not affect
Sarm1 NADase activity as assayed by the production of ADPR or
Nam (Fig. 4, D and E). Moreover, axonal treatment with 8Br–cADPR did not alter sTIR dimerization–induced cADPR production (Fig. 3 A), indicating that the neuroprotective effect of
8-Br–cADPR is downstream of Sarm1.
One discrepancy we noticed is that 8-Br–cADPR only partially
inhibited paclitaxel or Sarm1 activation–induced axonal calcium
flux but rescued the degeneration index completely to the
baseline level. This can be explained by technical differences in
the systems, timing, and paclitaxel concentrations used for calcium imaging versus axon degeneration assay. Sarm1 depletion,
as shown above, completely inhibited paclitaxel-induced calcium flux and degeneration. To compare the neuroprotective effects of Sarm1 depletion and inhibition of cADPR signaling, we
evaluated axon degeneration after various times of paclitaxel
treatment. We found that 8-Br–cADPR and knockdown of Sarm1
showed similar neuroprotection at 24 h of paclitaxel treatment.
Sarm1 depletion continued to show full protection 36 h after
paclitaxel treatment, at which time 8-Br–cADPR only partially
rescued the degeneration (Fig. S3 B), suggesting cADPR may be
Journal of Cell Biology
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levels induced by paclitaxel, we also examined the calcium signal
in CD38-depleted cultures. In direct contrast to Sarm1 knockdown,
CD38 knockdown further increased axonal calcium levels in axons
treated with paclitaxel without altering calcium signals in axons
treated with vehicle control (Fig. 2, C and D). Thus, the results
observed with calcium imaging closely parallel the enhanced
cADPR level that is seen in paclitaxel-treated, but not vehicletreated, CD38-depleted neurons. These results indicate that
changes in cADPR correlate well with axonal calcium levels and
that levels or dynamic changes of NAD and NADP do not show
this correlation.
To determine whether cADPR itself contributes to paclitaxelinduced axonal calcium flux, we tested the effects of 8-Br–cADPR,
a cell-permeable antagonist of cADPR, which blocks cADPRinduced calcium release in sea urchin egg homogenate (Walseth
and Lee, 1993) as well as in astrocytes and bone marrow neutrophils (Banerjee et al., 2008; Partida-Sanchez et al., 2007). We
found that treatment with 8-Br–cADPR together with paclitaxel in
axons partially decreased the axonal calcium flux compared with
axons treated with paclitaxel alone (Fig. 2, E and F), suggesting
cADPR is one of the factors that contributes to paclitaxel-triggered
calcium flux.
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one of multiple factors that mediate the axon-destructive effects
of Sarm1 upon paclitaxel treatment. These results collectively
demonstrate that cADPR-dependent calcium signaling contributes to paclitaxel-induced axon degeneration in vitro.
cADPR-targeted calcium channels are required for paclitaxelinduced axon degeneration
cADPR modulates intracellular calcium release through intracellular RyRs on the ER (Galione et al., 1991; Guse, 1999;
Li et al.
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Figure 3. Sarm1 activation triggers axonal calcium flux partially through cADPR. (A) Level of cADPR in cell bodies (CB) and distal axons (DA) from
compartmentalized cultures after 3 h of 50 nM B/B homodimerizer, 50 nM B/B homodimerizer together with 10 µM 8-Br–cADPR, or vehicle added to axons
following infection with lentivirus expressing FkbpF36V-sTIR. Data represent mean ± SEM; individual data points are shown. N represents four independent
experiments. For two samples of vehicle-treated cell bodies (CB) and one of distal axons (DA), no cADPR was detected. These data points are not shown.
(B) Representative images of GCaMP6s (green) and mRuby3 (red) of axons of DRG neurons expressing FkbpF36V-sTIR (top and middle) or FkbpF36V-mTIR
(bottom) 4 h after axonal treatment of 50 nM B/B homodimerizer together with 10 µM 8-Br–cADPR (middle) or saline (top and bottom). Arrowheads indicate
calcium elevated axons. Scale bar: 20 µm. (C) Quantification of calcium signal of B calculated as (GCaMP6s/mRuby3)/(GCaMP6s/mRuby3)0. (GCaMP6s/
mRuby3) represents calcium signal at each time point, and (GCaMP6s/mRuby3)0 represents calcium signal at time 0 before treatment. Data represent mean ±
SEM. N represents number of images. Eight images from each sample per experiment; two replicates per condition. Data pooled from four independent
experiments. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001 by two-way ANOVA with Tukey’s multiple comparisons test for each time point. (D) Quantification of
calcium signal of axons expressing FkbpF36V-sTIR before and after axonal treatment of 50 nM B/B homodimerizer alone or together with 10 µM 8-Br-7CH–cADPR. Data represent mean ± SEM. N represents number of images. Eight images from each sample per experiment; one or two replicates per condition
per experiment. Data pooled from five independent experiments. *, P < 0.05 by two-way ANOVA with Tukey’s multiple comparisons test for each time point.

Mészáros et al., 1993; Sonnleitner et al., 1998). As RyR3 is the
major type of RyR in DRG neurons (Lokuta et al., 2002), we
knocked down RyR3 using lentivirus-delivered shRNA (Fig. S4
A) and found that RyR3 depletion inhibited paclitaxel-induced
axon degeneration (Fig. 5, A and B). These data indicate that
RyR3-dependent calcium release from the ER contributes to
paclitaxel-induced degeneration. cADPR also directly binds to
and activates TRPM2, a calcium-permeable, nonselective cation
channel predominantly localized on the plasma membrane
Journal of Cell Biology
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(Kolisek et al., 2005; Yu et al., 2019). Knockdown of TRPM2 also
protects against paclitaxel-induced axon degeneration in DRG
cultures (Fig. 5, A and B; and Fig. S4 B). These results suggest
that calcium release from both intra- and extracellular sources
are required for axon degeneration downstream of paclitaxel.
To test whether RyR3 and TRPM2 open in response to activation of Sarm1, we coexpressed FkbpF36V-sTIR and shRNA
targeting RyR3 or TRPM2 individually in DRG neurons.
Knockdown of RyR3 or TRPM2 individually inhibited axon degeneration caused by sTIR dimerization (Fig. 5, C–E). In control
studies, dimerization of FkbpF36V-mTIR did not lead to axon
degeneration (Fig. S4 C). While cADPR-dependent calcium mobilization is known to be IP3R independent, knockdown of IP3R1
also suppressed axon degeneration caused by FkbpF36V-sTIR
Li et al.
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dimerization (Fig. 5 D and Fig. S4 D). Together these results
suggest that calcium signaling pathways independent of cADPR
also contribute to Sarm1 activation-induced degeneration, consistent with the idea that cADPR synergizes with other factors to
modulate calcium release and cause degeneration. These data
also indicate that both ER calcium stores and extracellular calcium are required for paclitaxel-induced intra-axonal calcium
influx and the ensuing axon degeneration.
Sarm1 activation also produces ADPR, the hydrolyzed form of
cADPR. Up to 20% of commercially available 8-Br–cADPR may
consist of 8-Br–ADPR, an antagonist of ADPR (Walseth, T.,
personal communication). As ADPR is a more potent ligand for
TRPM2 than cADPR (Huang et al., 2018; Kolisek et al., 2005; Yu
et al., 2019), we asked whether both components may contribute
Journal of Cell Biology
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Figure 4. Paclitaxel-induced axon degeneration is cADPR dependent. (A) Tuj1 immunostaining and corresponding binarized images of axons in compartmentalized cultures after 24 h of 30 nM paclitaxel (Pac), 30 nM paclitaxel with 10 µM 8-Br–cADPR, or DMSO (Veh) added to axons. White boxes outline
regions shown at higher magnification in the center panels. White stars indicate fragmented region of axons displayed as interruptions in Tuj1 continuity. Scale
bar: 20 µm (left and right panels), 50 µm (middle insets). (B) Degeneration index of A. Data represent mean ± SEM; individual data points are shown. N
represents number of images. Data pooled from 10 independent experiments. ****, P < 0.0001 by one-way ANOVA with Tukey’s multiple comparisons tests.
(C) Degeneration index of DRG axons after 24 h of DMSO (Veh) or 30 nM paclitaxel (Pac) with indicated concentrations of 8-Br-7-CH–cADPR. ****, P < 0.0001
by one-way ANOVA with Tukey’s multiple comparison tests. Data represent mean ± SEM. Individual data points are shown. N represents number of images.
Data pooled from three independent experiments. (D and E) Production rate of ADPR (D) and Nam (E) using purified Sarm1 protein supplemented with NAD
and NMN together with indicated dosages of 8-Br–cADPR. Data represent mean ± SEM. Data pooled from three independent experiments.
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Figure 5. Paclitaxel-induced axon degeneration requires both ER and extracellular calcium stores. (A) Tuj1 immunostaining and corresponding binarized
images of axons after 24 h of 30 nM paclitaxel (Pac) or DMSO (Veh) added to axons following lentiviral infection with RyR3 or TRPM2 or control shRNA (Ctl).
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White boxes outline regions shown at higher magnification in the center panels. White stars indicate fragmented region of axons displayed as interruptions in
Tuj1 continuity. Scale bar: 20 µm (left and right panels), 50 µm (middle insets). (B) Degeneration index of A. Data represent mean ± SEM. Individual data points
are shown. N represents number of images. Data pooled from three independent experiments. ****, P < 0.0001 by one-way ANOVA with Tukey’s multiple
comparisons tests. (C) Tuj1 immunostaining and corresponding binarized images of axons of DRG neurons coexpressing FkbpF36V-sTIR and indicated shRNA,
3 h after 50 nM B/B homodimerizer added to axons. White boxes outline regions shown at higher magnification in the center panels. White stars indicate
fragmented region of axons displayed as interruptions in Tuj1 continuity. Scale bar: 20 µm (left and right panels), 50 µm (middle insets). (D and E) Degeneration index of C. Data represent mean ± SEM. Individual data points are shown. N represents number of images. Data pooled from three independent
experiments. Two data points 0.199 and 0.208 of Ctl + sTIR + B/B that fall outside y axis limit not shown in F. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 by
one-way ANOVA with Tukey’s multiple comparisons test. (F and G) Degeneration index of DRG axons before and 6, 9, and 24 h after axotomy (F) or carbonyl
cyanide m-chlorophenylhydrazone (CCCP) treatment (G). ****, P < 0.0001 by one-way ANOVA with Tukey’s multiple comparisons tests. Data represent mean
± SEM. N represents number of images. Data pooled from three independent experiments. Axd, axon degeneration.

Antagonizing cADPR shows neuroprotective effects against
paclitaxel in vivo
Our results indicate that Sarm1 and cADPR are critical for
paclitaxel-induced axon degeneration in vitro. To assess the
roles of cADPR in paclitaxel-induced peripheral neuropathy
in vivo, we treated 2-mo-old C57BL6/J mice with multiple i.p.
injections of paclitaxel. Animals were concurrently treated with
8-Br–cADPR or saline control. We then evaluated paclitaxelinduced neuropathy in vivo at both behavioral and pathological levels (Fig. 6 A). A key feature of CIPN in patients is
allodynia, a condition in which pain is caused by stimuli that do
not normally elicit pain. To assess allodynia in mice before and
after paclitaxel, we compared the sensitivity of the mice to
mechanical stimuli using filaments of increasing rigidity (Von
Frey filament tests). A much smaller force triggered a withdrawal response in animals after paclitaxel treatment compared
with pretreatment baseline, while vehicle-treated control mice
showed no difference before and after treatment (Fig. 6 B). We
found that systemic treatment with 8-Br–cADPR significantly
suppressed paclitaxel-induced excess pain sensitivity (Fig. 6 B).
Loss of intra-epidermal nerve fiber (IENF) density is a canonical
pathological feature of CIPN consistently observed in both patients and animal models (Han and Smith, 2013). We collected
skin from the hind paws of the mice after the final behavior test
and examined IENF of both thin skin (nondermal papillaecontaining plantar metatarsal region) and thick skin (dermal
papillae-containing footpad region). Paclitaxel treatment significantly decreased IENF density in both thin (Fig. 6, C and D;
and Fig. S5 A) and thick (Fig. 6, C and E; and Fig. S5 B) skin
compared with vehicle-treated mice. Treatment with 8Br–cADPR provided partial protection from paclitaxel-induced
Li et al.
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loss of innervation (Fig. 6, C–E; and Fig. S5, A and B). There
were no significant body weight changes before and after
treatment with either paclitaxel alone or paclitaxel together
with 8-Br–cADPR (Fig. S5 C), indicating minimal nonspecific
toxicity of these treatments. These results demonstrate a neuroprotective effect of 8-Br–cADPR against paclitaxel-induced
peripheral neuropathy in vivo, suggesting that therapies targeting cADPR may be an effective strategy for CIPN.
cADPR antagonist does not interfere with paclitaxel’s antitumor effect
A concern in targeting cADPR for therapeutic purposes is the
possibility that this intervention might decrease the antineoplastic efficacy of paclitaxel, as calcium homeostasis is also
involved in cell cycle regulation and tumor progression (Stewart
et al., 2015; Yang et al., 2020). To address this, we used an immunocompetent breast cancer mouse model featuring the breast
cancer line E0771 in C57BL6/J mice. We implanted E0771 tumor
cells orthotopically into the mammary fat pads of 7-wk-old
C57BL6/J mice. We began paclitaxel injections 1 wk after tumor
cell injection, when the tumor size reached ∼5 mm in diameter.
To maximize the effect of paclitaxel on tumor growth, paclitaxel
or vehicle was injected every other day for a total of eight injections. 8-Br–cADPR or saline was injected after every two
paclitaxel or vehicle injections (Fig. 7 A). Tumor sizes increased
gradually in mice treated with vehicle + saline up to day 18 (Fig. 7
B), at which point some of these mice approached humane
endpoint. Treatment with 8-Br–cADPR alone did not alter tumor
growth (Fig. 7 B). Paclitaxel treatment significantly inhibited
tumor growth (Fig. 7 B), and combined treatment with paclitaxel
+ 8-Br–cADPR did not affect the ability of paclitaxel to suppress
tumor growth (Fig. 7 B), indicating that 8-Br–cADPR does not
interfere with the therapeutic efficacy of paclitaxel. Extended
treatment with paclitaxel led to a small but statistically significant weight decrease, while 8-Br–cADPR did not cause weight
changes when injected alone or with paclitaxel (Fig. 7 C). We
then further analyzed CIPN in these mice by evaluating IENF
innervation. IENF density of both thin and thick skins was significantly decreased in paclitaxel-treated mice compared with
vehicle control, and 8-Br–cADPR partially but significantly
rescued the IENF density loss in both thin and thick skins
(Fig. 7, D–F; and Fig. S5, D and E). Notably, 8-Br–cADPR
treatment alone did not affect IENF density (Fig. 7, E and F;
and Fig. S5, D and E). Together, our data demonstrate that
8-Br–cADPR protects against paclitaxel-induced allodynia
Journal of Cell Biology
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to the observed efficacy. We treated DRG axons with 8-Br–ADPR
and found 8-Br–ADPR also decreased paclitaxel-induced axon
degeneration (Fig. S4 E), consistent with our finding that TRPM2
and RyR both contribute to paclitaxel-induced degeneration.
Calcium dysregulation is also implicated in Sarm1-dependent
axon degeneration in response to physical injury. We asked
whether an antagonist of cADPR also protects against Wallerian
degeneration. Interestingly, we found 8-Br–cADPR does not
prevent axotomy or mitochondrial dysfunction–induced axon
degeneration (Fig. 5, F and G). Our data indicate that there are
qualitative and/or quantitative differences in the function of
cADPR between axon degeneration caused by axotomy and the
chemotherapeutic agent paclitaxel.
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and nerve fiber degeneration in vivo without affecting the
anti-tumor effect of paclitaxel, indicating it may provide a
good therapeutic approach to CIPN.

Discussion
cADPR as a calcium modulator in paclitaxel-induced axon
degeneration
Understanding the role of calcium dysregulation in chemotherapyinduced axon degeneration requires direct monitoring of axonal
calcium flux following drug treatment. In this study, we
directly visualized and analyzed axonal calcium flux after
paclitaxel treatment and demonstrated that local treatment
of paclitaxel causes a progressive increase of axonal calcium,
and this precedes axonal degeneration. While previous
studies have focused on cADPR as a readout of Sarm1 activity
(Sasaki et al., 2020), here we show that cADPR produced by
Li et al.
cADPR, Ca++, and axon degeneration in CIPN

Sarm1 activity contributes to paclitaxel-induced axonal calcium flux and degeneration. cADPR functions as a modulator
of both RyR and TRPM2, and we find that multiple calcium
channels, including RyR3, TRPM2, and IP3R1, all contribute
to axon degeneration initiated by paclitaxel or Sarm1 activation. Thus, multiple intra- and extracellular sources of
calcium are involved in axonal calcium flux caused by paclitaxel. A previous study from our laboratory showed that
paclitaxel treatment leads to decreased axonal levels of Bclw
protein, a Bcl2 family member that binds and regulates IP3R1.
Thus, paclitaxel both initiates Sarm1-dependent calcium flux
and attenuates Bclw-mediated suppression of IP3R1-mediated
calcium changes. We speculate that cADPR produced by activated Sarm1 together with Bclw depletion both contribute to a
complex process of calcium-induced calcium release to promote
axon degeneration. Further studies are needed to decipher the
initial versus later stages of calcium release in this cascade.
Journal of Cell Biology
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Figure 6. cADPR antagonist protects against paclitaxel-induced peripheral neuropathy in vivo. (A) Schematic of experimental design. Paclitaxel (Pac;
20 mg/kg) or vehicle was injected i.p. on days 1, 3, 5, and 7, and 8-Br–cADPR (2 mg/kg) or saline was injected i.p. on days 4 and 8. Final behavior test with Von
Frey filaments was performed on day 17, and mice were euthanized for IENF analysis on day 18. (B) Mechanical pain threshold assessments of mice using Von
Frey filaments before (Baseline) and 10 d after the final injection (Post-Treatment) of paclitaxel or vehicle control. Data represent mean ± SEM; individual data
points are shown. N represents number of animals. **, P < 0.01; ***, P < 0.001 by two-way ANOVA with Tukey’s multiple comparisons test. (C–E) Quantification and representative images of Tuj1-positive sensory fibers (green) entering the epidermis per 100-µm epidermal length in nondermal papillaecontaining thin (C, left, and D) and dermal papillae-containing thick (C, right, and E) skin. DAPI counterstain (blue); scale bar: 20 µm. **, P < 0.01; ****, P <
0.0001 by one-way ANOVA with Tukey’s multiple comparisons test. Data represent mean ± SEM; individual data points are shown. N represents number of
images; 6–10 images from each animal. Animal #: 8, 7, 11 (also see Fig. S5, A and B for statistics based on N = animal #). Veh, vehicle.
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In contrast to the efficacy of cADPR antagonists in preventing
CIPN both in vitro and in vivo, we found that a cADPR antagonist was
unable to prevent axotomy-induced axon degeneration. Our data indicate that although axonal degeneration triggered by paclitaxel and
axotomy are both Sarm1 dependent, the two signaling cascades are
functionally different. This is supported by the fact that paclitaxel
causes axonal depletion of Bclw, which leads to IP3R1-dependent calcium dysregulation, indicating multiple factors contribute to changes
in calcium regulation and the degeneration process in CIPN. Further
analyses will be required to identify the mechanisms that differentiate
slowly progressing Sarm1-dependent degeneration caused by paclitaxel from the more acute and severe perturbation of axotomy.
Li et al.
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Sarm1 activation downstream of paclitaxel
The mechanisms that activate Sarm1 are just beginning to be
defined. A recent study demonstrates that Sarm1 is a metabolic
sensor that can be allosterically regulated by the ratio of NMN
and NAD (Figley et al., 2021). Although we do not yet know how
paclitaxel activates Sarm1, an attractive idea is that paclitaxel
causes defective axon transport of NMNAT2, a highly labile
protein that converts NMN to NAD, and must be continuously
provided to the axon by fast axonal transport (Gilley and
Coleman, 2010). Indeed, depletion of the axon survival factor
NMNAT2 leads to Sarm1-dependent axon degeneration (Gilley
et al., 2015). We speculate that microtubule-dependent transport
Journal of Cell Biology
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Figure 7. 8-Br–cADPR does not alter paclitaxel’s anti-tumor effect in vivo. (A) Schematic illustration of experimental design. Paclitaxel (Pac) or vehicle
(Veh) was injected i.p. on day 1, 3, 5, 7, 9, 11, 13, and 15, and 8-Br–cADPR or saline was injected i.p. on day 4, 8, 12, and 16. Mice were euthanized for IENF
analysis on day 18. (B) Normalized tumor size of mice with E0771 breast cancer cells treated with vehicle + saline, paclitaxel + saline, paclitaxel + 8-Br–cADPR,
or vehicle + 8-Br–cADPR. Data represent mean ± SEM. N represents number of tumors. Five animals with bilateral tumors were used for each condition. **, P <
0.01; ****, P < 0.0001 by two-way ANOVA with Tukey’s multiple comparisons test at each time point. (C) Body weights of tumor-bearing mice treated with
vehicle + saline, paclitaxel + saline, paclitaxel + 8-Br–cADPR, or vehicle + 8-Br–cADPR. Data represent mean ± SEM. N represents number of animals. Five
animals were used for each condition. ***, P < 0.01 by two-way ANOVA with Tukey’s multiple comparisons tests at each time point. (D–F) Representative
images and quantification of Tuj1-positive sensory fibers (green) entering the epidermis per 100-µm epidermal length in nondermal papillae-containing thin (D,
left, and E) and dermal papillae-containing thick (D, right, and F) skin. DAPI counterstain (blue). Scale bar: 20 µm. Data represent mean ± SEM; individual data
points are shown. N represents number of images, 8–16 images from each animal. Animal# 5, 5, 5, 5 (also see Fig. S5, D and E for statistics based on N = animal
#). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 by one-way ANOVA with Tukey’s multiple comparisons test.
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Mouse line and animal care
All experimental procedures were conducted in accordance with
the National Institutes of Health (NIH) guidelines and were
approved by the Dana-Farber Cancer Institute or the Washington University School of Medicine, St. Louis Institutional Animal
Care and Use Committee.
Timed pregnant Sprague-Dawley rats and CD1 mice were
purchased from Charles River. C57BL6/J mice were purchased
from The Jackson Laboratory.

Tumor mouse model in CIPN research and therapeutic
implication of cADPR
Our in vivo studies corroborate the involvement of cADPR in
paclitaxel-induced peripheral neuropathy. Paclitaxel-treated mice
exhibit heightened pain sensitivity and loss of intra-epidermal
nerve endings, recapitulating the allodynia and dying-back
nerve degeneration observed in patients. I.p. administration
of 8-Br–cADPR attenuates paclitaxel-induced peripheral neuropathy both behaviorally and pathologically. The robust protection of 8-Br–cADPR in vivo, however, may involve other
components besides the nerve itself, since the role of cADPR as
a calcium modulator has also been implicated in the immune
system and in glial cells (Banerjee et al., 2008; Guse et al., 1999;
Partida-Sánchez et al., 2001). Nevertheless, our results raise the
possibility of using cADPR as a potential therapeutic target for
treating paclitaxel- and possibly other chemotherapy-induced
peripheral neuropathies.
Preventive treatments of CIPN will be given to patients who
are undergoing treatment for a malignant cancer. Therefore, in
searching for new therapies for CIPN, it is critical that the
neuropathic and anti-neoplastic effects of the microtubuletargeting chemo-drugs can be uncoupled from one another.
Using an immune competent mouse model of breast cancer, we
were able to examine both peripheral neuropathy progression
and tumor growth in the same animals. Consistent with prior
studies, we found that tumor growth was significantly inhibited
by paclitaxel in this model (Bourgeois-Daigneault et al., 2016)
and that these paclitaxel-treated mice also exhibited decreased
IENF density, confirming that paclitaxel causes peripheral
neuropathy in this model. Treatment with the cADPR competitive antagonist 8-Br–cADPR improved the paclitaxel-induced
neuropathy without interfering with its anti-tumor effect.
Thus, the effects of paclitaxel on cancer growth can potentially
be disentangled from its effects on nerve innervation. Our results in vitro and in vivo collectively indicate the potential of
targeting cADPR as a novel and promising therapeutic approach
for preventing paclitaxel-induced peripheral neuropathy. Further studies investigating the ability of new small-molecule inhibitors of Sarm1 (Hughes et al., 2021) to prevent or delay CIPN
in vivo without altering therapeutic effects of chemotherapies
may provide additional therapeutic approaches to this major
cause of poor quality of life in cancer survivors.

DRG neuron culture
DRGs were dissected from E15 rat embryos, dissociated, and
plated in Matrigel (1:45; Thermo Fisher Scientific)-coated p35
dishes, Campenot device, or poly-D-lysine/laminin-coated microfluidic chambers. DRG cultures were maintained in NeuroBasal medium supplemented with 2% B27, 1% Glutamax, 1%
penicillin and streptomycin, 0.08% glucose, 1–100 ng/ml nerve
growth factor (NGF)/brain-derived neurotrophic factor (BDNF;
PeproTech), and 0.5 µM Cytarabine (AraC). Cultures were
maintained in incubators at 37°C with 7.5% CO2. For noncompartmentalized mass culture, 300,000 cells were plated in
each p35 dish. BDNF + NGF was added at a concentration of
100 ng/ml for 2 d and reduced to 10 ng/ml for 5–6 d. Campenot
device was prepared as described (Fenstermacher et al., 2015).
BDNF + NGF was added to the cell body compartment at a
concentration of 10 ng/ml and to the axon compartment at a
concentration of 100 ng/ml for 2 d. On day 5, neurotrophins
were removed from the cell body compartment and reduced to
1 ng/ml in the axon compartments for 2–3 d. Paclitaxel (30 nM)
or DMSO (0.0025%) was added to the axon chambers on days
in vitro (DIV)7–8 for 24 h before fixation. For TIR domain dimerization, 50 nM B/B homodimerizer was added to the axon
chambers for 3 h before fixation. For degeneration assay with
8-Br–cADPR treatment, 8-Br–cADPR (0.1–10 µM) was added to
axon chambers 1 h before paclitaxel or B/B homodimerizer addition and continued to be present in the axon chambers with
paclitaxel or B/B homodimerizer until fixation.
Microfluidic chambers (Xona Microfluidics) were prepared
according to manufacturer’s instruction with laminin and polyD-Lysine coating. 30,000 neurons were plated in the cell body
compartment. BDNF + NGF was added to the cell body compartment at 50 ng/ml and to the axon compartment at 100 ng/ml
for 1 d and reduced to 10 ng/ml (cell bodies) and 100 ng/ml
(axons) for 1 d and maintained in 5 ng/ml (cell bodies) and 10 ng/
ml (axons) for 3–5 d. Paclitaxel (600 nM) or 0.5% DMSO was
added to axon compartments on DIV4–5 for 48 h. For TIR domain dimerization, 50 nM B/B homodimerizer was added to
the axon chambers on DIV4–5 for 4 h. For experiment with
8-Br–cADPR, 8-Br–cADPR was added to axon chamber 1 h before
paclitaxel or 50 nM B/B homodimerizer and continued to be
present in axon together with paclitaxel or B/B homodimerizer.
For axotomy-induced axon degeneration, mouse DRG cultures were prepared as described previously (Sasaki et al., 2016).
Briefly, DRG was dissected from embryonic days 13.5–14.5 CD1
mouse (Charles River Laboratories) and incubated with 0.05%
Trypsin solution at 37°C for 20 min. Then, cell suspensions were
triturated by gentle pipetting and washed with Neurobasal

Materials and methods
Key resources and reagents used in this study are listed in
Table S5.
Li et al.
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of NMNAT2 may be disrupted by paclitaxel, which leads to
NMNAT2 depletion, changes in the ratio of NMN and NAD, and
Sarm1 activation. Other molecules, including mitochondrial
antiviral signaling protein (MAVS) and syndecan-2 (Sdc2), have
been suggested as additional potential regulators of Sarm1 activity (Chen et al., 2011; Mukherjee et al., 2013). Thus, it is also
possible that transport of MAVS and/or Sdc2 may be impaired
following paclitaxel treatment, leading to changes in axonal
MAVS and/or Sdc2 that further activate Sarm1.
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culture medium (Gibco) containing 2% B27 (Invitrogen), 50 ng/
ml NGF (Envigo Bioproducts; Cat. #B5017), 1 µM uridine (SigmaAldrich), 1 µM 5-fluoro-2’-deoxyuridine (Sigma-Aldrich), penicillin, and streptomycin. Cell suspensions were placed in the
center of the well using a 24-well tissue culture plate (Corning)
coated with poly-D-Lysine (0.1 mg/ml; Sigma-Aldrich) and
laminin (3 µg/ml; Invitrogen).

Plasmids construction
For lentiviral constructs expression of Sarm1, RyR3, and CD38
shRNA, the following oligos were annealed and cloned into
pLKO.1 between AgeI and EcoRI following instructions provided
by Addgene (https://www.addgene.org/protocols/plko/): Sarm1:
For: 59-CCGGCAGGTAGATGGTGATTTGCTTctcgagAAGCAAAT
CACCATCTACCTGTTTTTTTG-39; Rev: 59-AATTCAAAAACAGGT
AGATGGTGATTTGCTTCTCGAGAAGCAAATCACCATCTACCTG39; RyR3: For: 59-CCGGAAGCTCCTGACAAATCACTATCTCGA
GATAGTGATTTGTCAGGAGCTTTTTTTG-39; Rev: 59-AATTCA
Li et al.
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Lentivirus generation and transduction
Lentivirus was generated following protocols provided by
Addgene (https://www.addgene.org/protocols/plko/). Briefly,
transfer plasmid, packaging plasmid cytomegalovirus (pCMV)dR8.91, and envelop plasmid pCMV-VSV-G were transfected
into HEK293T cells using FUGENE6 or Lipofectamine2000
following manufacturer’s instruction. The media containing
virus were harvested 48 and 72 h after transfection and pooled
and were then concentrated to ∼1/12 of the original volume
using Amicon Ultra-centrifugal filter. For lentivirus infection
of DRG neurons in compartmented Campenot cultures, 25–50
µl lentivirus was added to the middle chamber, which contains
cell bodies, on DIV2. For microfluidic culture, 100 µl lentivirus
of TIR domains or 25 µl lentivirus of shRNA was added to the
cell body chamber on DIV1.
Quantitative reverse transcription-PCR
RNA was extracted from DRG neurons using TRIzol (Invitrogen)
according to manufacturer’s instruction. Reverse transcription
was performed using the SuperscriptIII first-strand synthesis
(Thermo Fisher Scientific) according to the manufacturer’s instruction, and quantitative real-time PCR was performed using
Taqman Gene expression assays (Applied Biosystems) to analyze
expression of SARM1 (Rn01750947_m1), TRPM2 (Rn01429410_m1),
CD38 (Rn00565538_m1), and RyR3(Rn01486097_m1). Data were
normalized to GAPDH (Applied Biosystems) for each sample.
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LC-MS/MS analysis
Metabolites extraction was done following nucleotide extraction
protocol provided by the McGill metabolic core facility. Briefly,
both mass culture and Campenot culture were washed with
ice-cold 150 mM ammonium formate buffer and harvested in
ice-cold 50%/50% (vol/vol) methanol/LC-MS grade water, followed by three-solvent extraction (50% methanol/acetonitrile/
dichloromethane/water = 380 µl:220 µl:600 µl:300 µl). The
aqueous phase was then isolated and dried using vacuum centrifugation. For semiquantitative targeted metabolite analysis of
nucleotides, samples were injected onto an Agilent 6470 Triple
Quadrupole. Chromatography was achieved using a 1290 Infinity ultra-performance LC system (Agilent Technologies). Separation was performed on a Scherzo SM-C18 column 3 µm, 3.0 ×
150 mm (Imtakt Corp) maintained at 10°C. The chromatographic
gradient started at 100% mobile phase A (5 mM ammonium
acetate in water) with a 5-min gradient to 100% B (200 mM
ammonium acetate in 20% acetonitrile/80% water) at a flow rate
of 0.4 ml/min. This was followed by a 5-min hold time at 100%
mobile phase B and a subsequent reequilibration time (6 min)
before next injection. Samples were individually resuspended in
30 µl of cold water, and 5 µl volume was injected immediately
after sample preparation to help preserve unstable metabolites.
Multiple reaction monitoring (MRM) transitions were optimized on standards for each metabolite measured. MRM transitions and retention time windows are summarized in Table S4.
An Agilent JetStream electrospray ionization source was used in
positive ionization mode with gas temperature and flow set at
300°C and 5 liter/min, respectively; nebulizer pressure set at 45
psi; and capillary voltage set at 3,500 V. Relative concentrations
were determined from external calibration curves prepared in
water. Ion suppression artifacts were not corrected; thus, the
presented metabolite levels are relative to the external calibration curves and should not be considered as absolute concentrations. Data were analyzed using MassHunter Quant (Agilent
Technologies). The amount of each metabolite per sample was
normalized to cell number. See Table S4 for a summary of MRM
transitions and retention time windows

AAAAAAGCTCCTGACAAATCACTATCTCGAGATAGTGATTTG
TCAGGAGCTT-39; CD38: For: 59-CCGGGAGCATCCATCATGTAGACTTCTCGAGAAGTCTACATGATGGATGCTCTTTTTH-39; Rev:
59-AATTCAAAAAGAGCATCCATCATGTAGACTTCTCGAGAA
GTCTACATGATGGATGCTC-39.
The shRNA sequence was selected using BLOCK-iT RNAi
Designer provided by Thermo Fisher Scientific. Lentiviral constructs expressing shRNA targeting rat IP3R1 (TRCN0000321161)
and TRPM2 (TRCN0000068488) were purchased from SigmaAldrich.
FCIV-hSarm1, a full-length isoform of the canonical 724–
amino acid human SARM1, was introduced into lentivirus vector
FCIV using the Takara HD InFusion Cloning Kit and complimentary oligonucleotides. The expressed SARM1 protein contains optimized start codons K3, I4, H5 and is fused to 2 X Strep
Tag at the N-terminus. The absence of mutations and other PCR
errors was confirmed by sequencing (Genewiz). Generation of
FCIV-FkbpF36V-Sarm1-TIR and FCIV-FkbpF36V–Myd88-TIR
was previously described (Gerdts et al., 2015). Briefly, sTIR
(AA560-724) was PCR amplified from human SARM1; human
MYD-88 TIR (AA160-296) was synthesized as Gene Block fragments (IDT). Fkbp was PCR amplified from Cluc-Fkbp (Addgene;
#31184) from the laboratory of David PiwnicaWorms. FkbpF36V
variant was synthesized as a Gene Block (IDT). sTIR and mTIR
were fused between FkbpF36V and Cerulean with flexible
linkers and cloned into lentiviral FCIV vector.

Western blot
DRG neurons transduced with Sarm1, IP3R1, or control shRNA
for 6–7 d were lysed with nonionic detergent. Lysates were
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separated by 3–8% Tris-Acetate SDS-PAGE for IP3R1 and by
4–12% Bis-Tris SDS-Page for Sarm1 (Thermo Fisher Scientific)
and probed with mouse anti-Sarm1 (1:10,000; Chen et al., 2011),
rabbit anti-IP3R1 (1:1,000; Thermo Fisher Scientific; PA1-901),
and rabbit anti–pan-actin (1:1,000; Cell Signaling; 8456S). Bands
were visualized with secondary antibodies conjugated to HRP
(1:10,000; Bio-Rad; 1721019, 1706516) and SuperSignal chemiluminescent substrates signal (Thermo Fisher Scientific). Blots
were imaged using the AI600 Chemiluminescent Imager (GE
Healthcare).

Axotomy-induced axon degeneration assay
Mouse DRG neurons were placed in the center of the well using a
24-well tissue culture plate. On DIV7, 1 or 10 µM 8-Br–cADPR
was preincubated 30 min before axon injury. Axons from DRG
neurons were either transected using a microsurgical blade
under a microscope or applied with 50 µM carbonyl cyanide
m-chlorophenylhydrazone for axon degeneration assay. Brightfield images of distal axons (20 fields/well and 3 wells/conditions)
were acquired at 0–24 h after axon injury using a high-content
imager (Operetta; PerkinElmer) with a 20× water objective lens.
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Calcium imaging
E15 DRG neurons in microfluidic devices were transduced
on DIV1 with 5–10 µl AAV9-axonal-GCaMP6s-P2A-mRuby3
(Broussard et al., 2018; AAV9 was generated by Applied Biological Materials) alone or together with 25 µl lentivirus expressing shRNA-targeting tGFP, Sarm1, or CD38 for 24 h.
Cultures were maintained in phenol red-free NeuroBasal medium supplemented with 2% B27, 1% Glutamax, 1% penicillin and
streptomycin, 0.08% glucose, NGF/BDNF, and 0.5 µM AraC for
4–5 d before imaging. For neurons transduced with lentivirusexpressing shRNA, 1 µg/ml puromycin was added to the cell
body on DIV3 for 2 d for selection and was removed before
imaging. 8–10 fields of axon chamber for each sample were
imaged using NIS-elements (Nikon) with a Nikon Ti-E at 37°C
(60× oil, 1.4 NA objective) with 7.5% CO2 before treatment as
time zero. Then, 600 nM paclitaxel or 0.5% DMSO was added to
axon compartments. Cultures were maintained in incubators at
37°C with 7.5% CO2. The same fields of axons for each sample
were imaged manually at 12, 16, 20, 24, 36, 40, 44, and 48 h after
treatment. For experiments with 8-Br–cADPR, 20 µM 8-Br–cADPR
was added to axon chamber 1 h before paclitaxel and continued to
be present in axon together with paclitaxel.
For FkbpF36V-sTIR–induced calcium flux, DIV1 DRG neurons
were transduced with 5–10 µl AAV9-axonal-GCaMP6s-P2AmRuby3 together with 100 µl lentivirus expressing FkbpF36VsTIR or FkbpF36V-mTIR. Cultures were maintained in phenol
red-free NeuroBasal medium supplemented with 2% B27, 1%
Glutamax, 1% penicillin and streptomycin, 0.08% glucose, NGF/
BDNF, and 0.5 µM AraC for 4–5 d before imaging. Expressions of
FkbpF36V-sTIR or mTIR were verified based on Cerulean expression. Eight fields of axon chamber for each sample were
imaged before treatment and every 1 h after addition of 50 nM
B/B homodimerizer to the axon chamber. For experiments with
8-Br–cADPR, 10 µM 8-Br–cADPR was added to axon chamber 1 h
before 50 nM B/B homodimerizer was added and continued to
be present in the axon chamber.
Both GCaMP6s (FITC channel) and mRuby3 (TRITC channel)
signals were acquired using NIS-elements (Nikon) at each time
point using the Nikon Ti-E at 37°C (60× oil, 1.4 NA objective)
with 7.5% CO2. Images were analyzed using NIH ImageJ
software. For each field at each time point, background signal was subtracted for the individual fluorescent channel
using ImageJ default “Subtract Background” function. Then,
axon area was selected based on mRuby3 signal using the
embedded “MinError” threshold setting. Then, GCaMP6s and
mRuby3 fluorescence intensities within the defined axon
area were measured. The axonal GCaMP6s for each field
at each time point was normalized to the corresponding
mRuby3 intensity. The change in fluorescence was measured
per field of axons using the equation [(GCaMP6s/mRuby)/
(GCaMP6s/mRuby)0], where (GCaMP6s/mRuby)0 is the baseline at time 0 before treatment. Treatments and the corresponding controls were done in parallel for each independent
experiment.
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Axonal degeneration assay
Neurons in Campenot cultures were fixed at room temperature
with 4% PFA diluted 1:2 in media for 10 min, then undiluted 4%
PFA for an additional 20 min. Cultures were permeabilized and
blocked in 3% BSA and 0.1% Triton X-100 for 1 h at room temperature and incubated with mouse anti-Tuj1 (1:500; BioLegend;
801213) overnight at 4°C. Cultures were then washed twice
with PBS and incubated with goat anti-mouse Alexa Fluor
(1:400; Invitrogen; A11001) and DAPI for 1 h at room temperature. Campenot dividers were then removed, and samples were mounted with Fluoromount-G (Southern Biotech;
0100–01). Images of distal axon tips were obtained using NIS
elements imaging software (Nikon) with a Nikon Eclipse
E800 microscope with a 40× air objective and a Nikon Digital
Sight DS U2 camera at room temperature; images were
analyzed using ImageJ. Images were binarized, and axonal
degeneration was quantified as degeneration index ratio of
fragmented axons (particle size: 1–1,000) divided by total
axon area in each image (Pease-Raissi et al., 2017; Sasaki
et al., 2009).
Neurons in microfluidic cultures were permeabilized and
blocked in 3% BSA and 0.1% Triton X-100 for 1 h at room temperature and incubated with mouse anti-Tuj1 (1:500; BioLegend;
801213) overnight at 4°C. Cultures were then washed twice with
PBS and incubated with donkey anti-mouse Alexa Fluor 488 (1:
400; Invitrogen; A11001) and DAPI for 1 h at room temperature.
Teflon dividers were then removed, and samples were mounted
with Fluoromount-G (Southern Biotech; 0100–01). Images of
10–20 fields of axons for each sample were acquired using NIS
elements imaging software (Nikon) with a Nikon Ti-E at room
temperature (60× oil, 1.4 NA objective). The same XY positions
were imaged for treatments and control for each experiment.
Images were binarized, and axon area was measured using NIH
ImageJ software. Data were then normalized to DMSO-treated
control.

Axon degeneration was quantified using degeneration index calculated with ImageJ.
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Sarm1 in vitro activity assay
Sarm1 in vitro activity was assessed as described previously with
modification (Essuman et al., 2017). Briefly, human SARM1
(15 nM)–laden beads were mixed with various concentrations of
8-Br–cADPR in 50 mM Hepes, pH 7.5, 50 µM NAD, and 25 µM
NMN at 25°C. Reaction was performed in a ThermoMixer. At
various time points, the reaction was stopped by taking 50 µl from
the reaction mixture and mixing with 50 µl 0.5M perchloric acid
(HClO4) before placing on ice for 10 min. After centrifugation at
18,000×g for 10 min, supernatant was mixed with 6 µl 3M K2CO3
for neutralization. Samples were placed on ice for another 10 min
and centrifuged one more time. 45 µl of supernatant containing
extracted metabolites was mixed with 5 µl 0.5 M potassium
Pphosphate buffer and quantified by HPLC (Nexera X2) with Kinetex (100 × 3 mm, 2.6 µm; Phenomenex) column. ADPR and Nam
production rates were calculated from samples taken at various
time points at each 8-Br–cADPR concentration.
Paclitaxel treatment in vivo and behavioral testing
2-mo-old C57BL6/J mice (18–25 g) of both sexes were injected i.p.
with 20 mg/kg paclitaxel (Bristol-Myers Squibb) every other
day (days 1, 3, 5, and 7, for a total of four injections), while
2 mg/kg 8-Br–cADPR was injected after every two paclitaxel
injections (days 4 and 8, for a total of two injections). Paclitaxel
was prepared in one part vehicle (1:1 vol/vol Cremophor EL
[EMD Millipore] and 200-proof ethanol) and two parts sterile
saline (UPS) and injected at 10 µl/g. Control mice were injected
with one part vehicle and two parts saline. 8-Br–cADPR (SigmaAldrich) was prepared in sterile saline and injected at 10 µl/g,
and control mice were injected with saline. Mice were habituated for 2 d, and baseline behavioral performance was assessed
over the next 2 d and averaged. The first paclitaxel injection (day
1) was given 3 d later, and mice were behaviorally tested 9 d after
the final injection (day 17). Noxious mechanosensation threshold
was assayed as described previously (Pease-Raissi et al., 2017)
using Von Frey filaments (0.008–1.4 g). Withdrawal threshold
was determined to be the applied force at which the animal
withdrew the stimulated paw on at least 2 of 10 applications.
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Tumor-bearing mice
E0771 mouse breast tumor cells (American Type Culture Collection) were injected (2 × 105 cells/injection) orthotopically into the
thoracic fat pads of 2-mo-old C57BL/6J female mice (The Jackson
Laboratory) in 40% Matrigel. 7 d after tumor cells injection, paclitaxel or vehicle was injected i.p. every other day for 16 d (days 1, 3, 5,
7, 9, 11, 13, and 15, for a total of eight injections; 4 mg/kg for the first
two injections and 20 mg/kg for the remaining six injections).
8-Br–cADPR or saline was injected i.p. after every two injections of
paclitaxel (days 4, 8, 12, and 16, for a total of four injections; 2 mg/kg
each injection). Tumor size and animal weight were measured
before the first paclitaxel injection and every 3–4 d after. Tumor size
was assessed by measuring the long and short axes, and volume was
calculated by use of the modified ellipsoid formula (long × short2 ×
0.5). The size of each tumor was normalized to the tumor size acquired on the day before the first injection of paclitaxel.
Epidermal footpad innervation
Mice hindpaw footpads were prepared as described (PeaseRaissi et al., 2017). Briefly, mice were euthanized with isoflurane, and footpad tissue was removed and divided into thick
(dermal papillae-containing footpad region) and thin (nondermal papillae-containing plantar metatarsal region) skin.
Footpads were fixed in Zamboni’s fixative overnight at 4°C,
cryopreserved in 30% sucrose in PBS for 2 d at 4°C, frozen, and
sectioned into 30-µm floating sections. Sections were permeabilized and blocked with 0.1% Triton X-100 in PBS supplemented with 10% normal goat serum for 1 h at room temperature
and incubated with mouse anti-Tuj1 (1:300; BioLegend; 801213)
overnight at 4°C. Sections were then incubated with goat antimouse Alexa Fluor 488 (1:200; Invitrogen; A11001) and DAPI
(1:1,000; Invitrogen) for 2 h at room temperature and mounted
on gelatin-coated slides. IENF images were acquired using NISelements (Nikon) on a Nikon Ni-E C2 confocal with a 40×, 1.3 NA
oil objective as 30–31-µm z-stacks at room temperature and
converted to maximum-intensity projection image for quantification. IENF density was counted and calculated as the number
of Tuj1-positive fibers extending into the epidermis per 100-µm
epidermal length. Epidermal length was determined using the
embedded “measure length” function of NIS-elements (Nikon).
Quantification and statistical analysis
Data are expressed as mean ± SEM. For grouped data multiple
comparisons, data were analyzed by two-way ANOVA with Tukey’s multiple comparisons test. For columned data multiple
comparisons, data were analyzed by one-way ANOVA with Tukey’s multiple comparisons test. For calcium imaging, data were
analyzed by two-way ANOVA, and data at each time point were
compared using Tukey’s multiple comparisons test. Significance
was placed at *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Statistical analysis was done using GraphPad Prism. Data distribution was assumed to be normal, but this was not formally tested.
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Expression and purification of Sarm1 protein
Human SARM1 was transfected to a 150-mm–diameter cell
culture dish with 50% confluence of HEK293T cells. 15 µg of
plasmid was mixed with 75 µg of polyethylenimine (1 mg/ml, pH
7.0) and transfected to the cells. Cells were harvested 48 h after
transfection and resuspended in 100 mM Tris-Cl, pH 8.0, and
150 mM NaCl with Protease Inhibitor Cocktail (Pierce) before
being lysed with sonication on ice. After centrifugation at
18,000×g for 10 min and three times to remove the cell debris,
supernatant was mixed with PureCube HiCap Streptactin
MagBeads (Cube Biotech) for 1 h. After washing three times with
25 mM Hepes, pH 7.5, and 150 mM NaCl, SARM1-laden beads
were stored in the same buffer plus 1 mM tris(2-carboxyethyl)
phosphine and were stored at −80°C. Protein purity was assessed by 4–12% SDS-PAGE by Coomassie staining. Protein
concentration was determined using ImageJ (NIH) against BSA
standard with known concentrations running on the same SDSPAGE.

Online supplemental material
Fig. S1 presents data related to Fig. 1: verification of knockdown
by shRNAs targeted to Sarm1 and CD38; CD38 depletion alone
does not lead to axon degeneration in DRG neurons, and
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Data availability
Further information and requests for resources and reagents
should be directed to and will be fulfilled by the lead contact,
Rosalind Segal (rosalind_segal@dfci.harvard.edu).
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paclitaxel does not affect ADPR levels in vitro. Fig. S2 presents
data related to Fig. 2: paclitaxel decreases overall axon area in a
dose-dependent fashion in DRGs, and axonal degeneration
follows calcium elevation in paclitaxel-treated DRGs. Fig. S3
presents data related to Fig. 3 and Fig. 4: schematic illustration
of chemical-induced sTIR dimerization and Sarm1 depletion
provided stronger neuroprotection against paclitaxel than 8-Br–
cADPR in vitro. Fig. S4 presents data related to Fig. 5: verification
of knockdown by shRNAs targeted to RyR3, IP3R1, and TRPM2,
mTIR dimerization does not cause axon degeneration, and 8-Br–ADPR
protects against paclitaxel-induced axon degeneration in vitro. Fig. S5
presents data related to Fig. 6 and Fig. 7: 8-Br–cADPR protects against
paclitaxel-induced peripheral neuropathy in vivo without causing
weight change of animals.
Table S1, Table S2, Table S3, Table S4, and Table S5 present
statistics results of Fig. 1, D–F, summary of MRM transitions and
retention time windows of LC-MS, and key resources and reagents.
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Figure S1. Verification of knockdown by shRNAs targeted to Sarm1 and CD38, CD38 depletion alone does not lead to axon degeneration in DRG
neurons, and paclitaxel does not affect ADPR levels in vitro. (A) Normalized mRNA level of DRG neurons showing knockdown efficiency of Sarm1 shRNA
compared with tGFP-control shRNA. Data represent mean ± SEM; individual data points are shown. N represents three independent experiments. (B) Western
blot probed against Sarm1 and pan-actin showing knockdown efficiency of Sarm1 shRNA in DRG neurons. (C) Normalized mRNA level of DRG neurons showing
knockdown efficiency of CD38 shRNA compared with tGFP-control shRNA. Data represent mean ± SEM; individual data points are shown. N represents three
independent experiments. (D) Tuj1 immunostaining and corresponding binarized images of DRG axons transduced with Sarm1 shRNA or CD38 shRNA treated
with DMSO (Veh). Scale bar: 20 µm (left and right panels), 50 µm (middle insets). (E) ADPR level in cell bodies (CB) and distal axons (DA) of DRGs after 24 h of
30 nM paclitaxel (Pac) or DMSO (Veh) added to axons. Data represent mean ± SEM; individual data points are shown. N represents four independent
experiments.
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Figure S2. Paclitaxel decreases overall axon area in a dose-dependent fashion in DRGs, and axonal degeneration follows calcium elevation in
paclitaxel-treated DRGs. (A) Tuj1 immunostaining and corresponding binarized images of axons of DRG neurons after 48 h of 30 nM or 600 nM paclitaxel or
DMSO. Scale bar: 20 µm. (B) Normalized area of axons after 48 h of 30 nM or 600 nM paclitaxel or DMSO applied to axons. Data represent mean ± SEM;
individual data points are shown. N represents number of images, with 10–20 images of each sample from one or two samples per experiment and three
independent experiments. ****, P < 0.0001 by one-way ANOVA with Tukey’s multiple comparisons test. (C) Representative images of GCaMP6s (green) and
mRuby3 (red) of axons of DRG neurons expressing tGFP shRNA (Ctl) or Sarm1 shRNA after 48 h of DMSO (Veh) or 600 nM paclitaxel (Pac) treatment. White
arrowheads indicate axon with increased calcium at 36 h and degenerated at 48 h (also see Fig. 2 A). Scale bar: 20 µm.
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Figure S3. Schematic illustration of chemical-induced sTIR dimerization and Sarm1 depletion provided stronger neuroprotection against paclitaxel
than 8-Br–cADPR in vitro. (A) Schematic illustration: B/B homodimerizer binds to Fkbp-F36V and triggers FkbpF36V-sTIR dimerization followed by NADase
activation. (B) Degeneration index of DRG axons with or without Sarm1 shRNA expression after 12, 24, and 36 h of DMSO (Veh) or 30 nM paclitaxel (Pac) with
pretreatment of indicated concentrations of 8-Br–ADPR. **, P < 0.01; ****, P < 0.0001 by one-way ANOVA with Tukey’s multiple comparisons test. Data
represent mean ± SEM; individual data points are shown. N represents number of images. Data pooled from three independent experiments.
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Figure S4. Verification of knockdown by shRNAs targeted to RyR3, IP3R1, and TRPM2; mTIR dimerization does not cause axon degeneration; and
8-Br–ADPR protects against paclitaxel-induced axon degeneration in vitro. (A and B) Normalized mRNA levels of DRG neurons showing knockdown
efficiency of RyR3 shRNA (A) and TRPM2 shRNA (B). Data represent mean ± SEM; individual data points are shown. N represents three independent experiments. (C) Degeneration index of DRG axons transduced with lentivirus expressing FkbpF36V-mTIR with or without 50 nM B/B homodimerizer treatment
for 3 h. Data represent mean ± SEM. N represents number of images. Individual data points are shown. Data pooled from three independent experiments.
(D) Western blot probed against IP3R1 and pan-actin showing knockdown efficiency of IP3R1 shRNA in DRG neurons. (E) Degeneration index of DRG axons after
24 h of DMSO (Veh) or 30 nM paclitaxel (Pac) with indicated concentrations of 8-Br–ADPR. **, P < 0.01; ****, P < 0.0001 by one-way ANOVA with Tukey’s
multiple comparison test. Data represent mean ± SEM; individual data points are shown. N represents number of images. Data pooled from three independent
experiments. Ctl, control.
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Figure S5. 8-Br–cADPR protects against paclitaxel-induced peripheral neuropathy in vivo without causing weight change of animals. (A and B)
Quantification of Tuj1-positive sensory fibers (green) entering the epidermis per 100-µm epidermal length in nondermal papillae-containing thin (A) and dermal
papillae-containing thick (B) skin isolated from normal mice treated with indicated drug combination. Data represent mean ± SEM. N represents number of
animals. Individual data point shown represents the mean of 6–10 images taken from individual animal (also see Fig. 6, D and E). (C) Body weights of animals
before (Baseline) and after treatment (Post-treatment). Data represent mean ± SEM; individual data points are shown. N represents number of animals. (D and
E) Quantification of Tuj1-positive sensory fibers (green) entering the epidermis per 100-µm epidermal length in nondermal papillae-containing thin (D) and
dermal papillae-containing thick (E) skin isolated from E0771 cancer mice treated with indicated drug combination. Data represent mean ± SEM. N represents
number of animals. Individual data point shown represents the mean of 8–16 images taken from individual animal (also see Fig. 6, D and E). *, P < 0.05; **, P <
0.01; ***, P < 0.001. Pac, paclitaxel; Veh, vehicle.

Provided online are five tables. Table S1 presents statistical analysis of NAD level shown in Fig. 1 D. Table S2 presents statistical
analysis of NADP level shown in Fig. 1 E. Table S3 presents statistical analysis of cADPR level shown in Fig. 1 F. Table S4 summarizes
MRM transitions and retention time windows. Table S5 presents key resources.
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